| You are here: Home: BCU 8|2004: Daniel R Budman, MD: Select publications
Select publications
Blum JL et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17(2):485-93. Abstract
Crivellari D et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII. J Clin Oncol 2000;18(7):1412-22. Abstract
Fujimoto-ouchi K et al. Antitumor activity of combinations of anti HER2 neu antibody trastuzumab and oral fluoropyrimidines capecitabine / 5’DFurd in human breast cancer models. Cancer Chemother Pharmacol 2002;211-16. Abstract
Ishitsuka H. Capecitabine: Preclinical pharmacology studies. Invest New Drugs 2000;18(4):343-54. Abstract
Miles D et al. Survival benefit with Xeloda (capecitabine)/Taxotere (docetaxel) (XT) versus Taxotere: Analysis of post-study therapy. 2001 San Antonio Breast Cancer Symposium, Poster 442. Abstract 287.
O’Shaughnessy J et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20(12):2812-23. Abstract
O’Shaughnessy JA et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as firstline therapy for advanced/metastatic breast cancer. Ann Oncol 2001;12(9):1247-54. Abstract
Pegram M et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18(13):2241-51. Abstract
Schuller J et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000;45(4):291-7. Abstract
|
